ACIPHEX

Compare ACIPHEX  to:
Compare
Compare

Generic Name for ACIPHEX

Rabeprazole sodium 20mg; delayed-release, e-c tabs.

Legal Classification:

Rx

Pharmacological Class for ACIPHEX

Proton pump inhibitor.

Manufacturer of ACIPHEX

PriCara

Indications for ACIPHEX

Triple therapy (w. amoxicillin + clarithromycin) for H. pylori eradication in duodenal ulcer disease. Short-term treatment of erosive or ulcerative gastroesophageal reflux disease (GERD) or duodenal ulcers. Treatment of symptomatic GERD in patients ≥12 years of age. Maintenance of healing and reduction in relapse rates of heartburn symptoms in erosive or ulcerative GERD. Long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

Adult dose for ACIPHEX

Swallow whole. ≥18 years: Triple therapy: rabeprazole 20mg + amoxicillin 1g + clarithromycin 500mg, all twice daily (w. AM and PM meals) for 7 days. GERD healing: 20mg once daily for 4–8 weeks; may repeat for 8 more weeks. GERD symptoms: 20mg once daily for 4 weeks; may repeat for 4 more weeks. GERD maintenance: 20mg once daily. Duodenal ulcer healing: 20mg once daily after breakfast for up to 4 weeks. Hypersecretory conditions: initially 60mg once daily; titrate; doses up to 100mg once daily or 60mg twice daily have been used.

Children's dosing for ACIPHEX

<12 years: not recommended. ≥12 years: Short-term treatment of GERD: 20mg once daily for up to 8 weeks.

Precautions for ACIPHEX

Severe hepatic impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for ACIPHEX

May alter absorption of gastric pH-dependent drugs (eg, ketoconazole, digoxin). May give antacids concomitantly. May antagonize atazanavir (not recommended). Monitor warfarin, cyclosporine.

Adverse Reactions for ACIPHEX

Headache, pain, pharyngitis, flatulence, infection, constipation. Children: also nausea.

How is ACIPHEX supplied?

Tabs—30, 90

Related Disease:

Duodenal ulcers {DU}
GERD {GERD}
Hypersecretory conditions~Zollinger-Ellison syndrome
Ulcers, duodenal

Related Resources

Kapidex to be marketed under new trade name Dexilant

March 04, 2010

Takeda Pharmaceuticals announced that Kapidex (dexlansoprazole delayed-release capsules) will now be marketed under a new product trade name, Dexilant, due to reports of dispensing errors.

FDA warns of Maalox Total Relief medication errors

February 18, 2010

The FDA and Novartis Consumer Health have notified healthcare professionals about reports of serious medication errors involving patients who used Maalox Total Relief (bismuth subsalicylate) when they had intended to use a Maalox liquid antacid.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

McNeil Consumer Healthcare recalls certain over-the-counter (OTC) products

January 15, 2010

McNeil Consumer Healthcare and the FDA have announced a voluntary recall of certain lots of over-the-counter products, including Tylenol (acetaminophen), Motrin IB (ibuprofen), St. Joseph Aspirin (aspirin), Simply Sleep (diphenhydramine), and Rolaids (calcium carbonate and magnesium hydroxide).

Zegerid OTC approved for frequent heartburn

December 02, 2009

The FDA has approved Zegerid OTC (omeprazole/sodium bicarbonate capsules, from Merck) for the over-the-counter treatment of frequent heartburn.